The DOI matches its Crossref record.
The Price Tag on Progress — Chemotherapy for Colorectal Cancer
Abstract
From the 1960s until the mid-1990s, fluorouracil was the primary chemotherapeutic agent available for the treatment of colorectal cancer. During the past decade, the Food and Drug Administration (FDA) has approved five new drugs for metastatic colorectal cancer. Irinotecan (approved in 1996) and oxaliplatin (2002) are cytotoxic agents that interfere with DNA replication, and capecitabine (1998) is an oral formulation of fluorouracil. This spring, the monoclonal antibodies bevacizumab and cetuximab, targeting vascular endothelial growth factor and epithelial growth factor receptor, respectively, were approved by the FDA for use in conjunction with cytotoxic regimens.Better systemic therapy has considerably improved prognosis. . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Projections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Weitz, J., Koch, M., Debus, J., Höhler, T., Galle, P. R., & Büchler, M. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17706-x · Cited by 1,098
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Carrera, P. M., Kantarjian, H. M., & Blinder, V. S. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21443 · Cited by 876
Cost of Care for Elderly Cancer Patients in the United States
Yabroff, K. R., Lamont, E. B., Mariotto, A., Warren, J. L., Topor, M., Meekins, A., & Brown, M. L. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn103 · Cited by 700
Folprecht, G., Grothey, A., Alberts, S., Raab, H.-R., & Köhne, C.-H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi246 · Cited by 632
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1971 · Cited by 575
Systemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research
Yabroff, K. R., Lund, J., Kepka, D., & Mariotto, A. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0650 · Cited by 503
Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Kerbel, R. S. (2006) · Science · doi:10.1126/science.1125950 · Cited by 466
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 458
Pricing in the Market for Anticancer Drugs
Howard, D. H., Bach, P. B., Berndt, E. R., & Conti, R. M. (2015) · Journal of Economic Perspectives · doi:10.1257/jep.29.1.139 · Cited by 444
Cost-effectiveness of colorectal cancer screening – An overview
Lansdorp-Vogelaar, I., Knudsen, A. B., & Brenner, H. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.04.004 · Cited by 438
Matsuyama, R., Reddy, S., & Smith, T. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6236 · Cited by 403
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Bach, P. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmhpr0807774 · Cited by 390
Evaluation of Trends in the Cost of Initial Cancer Treatment
Warren, J. L., Yabroff, K. R., Meekins, A., Topor, M., Lamont, E. B., & Brown, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn175 · Cited by 388
Cost of Cancer Care: Issues and Implications
Meropol, N. J., & Schulman, K. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6081 · Cited by 351
Sartore-Bianchi, A., Moroni, M., Veronese, S., Carnaghi, C., Bajetta, E., Luppi, G., Sobrero, A., Barone, C., Cascinu, S., Colucci, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5956 · Cited by 333
The Role of Chemotherapy at the End of Life: “When Is Enough, Enough?”
Harrington, S. E., & Smith, T. J. (2008) · JAMA · doi:10.1001/jama.299.22.2667 · Cited by 280
Positive Surgical Margins in the 10 Most Common Solid Cancers
Orosco, R. K., Tapia, V. J., Califano, J. A., Clary, B., Cohen, E. E. W., Kane, C., Lippman, S. M., Messer, K., Molinolo, A., Murphy, J. D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23403-5 · Cited by 279
Lubner, S. J., Mahoney, M. R., Kolesar, J. L., LoConte, N. K., Kim, G. P., Pitot, H. C., Philip, P. A., Picus, J., Yong, W.-P., Horvath, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4075 · Cited by 267
Cancer treatment cost in the United States: Has the burden shifted over time?
Tangka, F. K., Trogdon, J. G., Richardson, L. C., Howard, D., Sabatino, S. A., & Finkelstein, E. A. (2010) · Cancer · doi:10.1002/cncr.25150 · Cited by 156
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Assessing Patient Readiness for the Clinical Adoption of Personalized Medicine
Issa, A. M., Tufail, W., Hutchinson, J., Tenorio, J., & Baliga, M. P. (2009) · Public Health Genomics · doi:10.1159/000189629 · Cited by 52
“However, pharmacogenomic-based diagnostics and therapeutics have not yet been fully incorporated into routine clinical practice.The increasingly swift pace of technological development in genomics science could lead to the endorsement and adoption of pharmacogenomic-based diagnostics and therapeutics without sufficien…”
BackgroundCosta, S., Bentley, C., Regier, D. A., McTaggart-Cowan, H., Mitton, C., Burgess, M. M., & Peacock, S. J. (2019) · BMC Public Health · doi:10.1186/s12889-019-7303-2 · Cited by 22
Metadata
- Authors
- Schrag, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-07-22
- Volume
- 351
- Issue
- 4
- Pages
- 317-319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2069703793
- Cited by
- 436
- References
- 0
- FWCI
- 19.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.